| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/JCP.1101 |
| P8608 | Fatcat ID | release_cwnoaudzfngoteij6rhjrlavga |
| P698 | PubMed publication ID | 11382926 |
| P2093 | author name string | Clayman GL | |
| Sun SY | |||
| Yue P | |||
| Guan B | |||
| P2860 | cites work | Characterization of two receptors for TRAIL | Q24309064 |
| The receptor for the cytotoxic ligand TRAIL | Q24310481 | ||
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| Identification and characterization of a new member of the TNF family that induces apoptosis | Q24318423 | ||
| The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain | Q24320162 | ||
| Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family | Q24320301 | ||
| Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL | Q24554360 | ||
| p53, the cellular gatekeeper for growth and division | Q27860990 | ||
| WAF1, a potential mediator of p53 tumor suppression | Q27861121 | ||
| The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract | Q28141340 | ||
| Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors | Q28245164 | ||
| KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene | Q28250929 | ||
| Death receptors: signaling and modulation | Q28280897 | ||
| Induction of the growth inhibitor IGF-binding protein 3 by p53 | Q28289896 | ||
| Apoptosis by death factor | Q28304002 | ||
| The TRAIL to selective tumor death | Q28504568 | ||
| A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia | Q29615437 | ||
| Mechanisms of p53-mediated apoptosis | Q33538150 | ||
| Regulation of p53 downstream genes. | Q33547816 | ||
| p53 and apoptosis | Q33547818 | ||
| Apoptosis control by death and decoy receptors | Q33597389 | ||
| Death by design: mechanism and control of apoptosis | Q33803998 | ||
| Role of p53 family members in apoptosis | Q33810088 | ||
| Safety and antitumor activity of recombinant soluble Apo2 ligand | Q33855449 | ||
| Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. | Q34469691 | ||
| p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs | Q36401199 | ||
| Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression | Q36551292 | ||
| Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment | Q39444883 | ||
| p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. | Q40897440 | ||
| Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells | Q40954596 | ||
| Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. | Q40975748 | ||
| Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. | Q42487048 | ||
| A novel form of Epstein-Barr virus latency in normal B cells in vivo | Q45789413 | ||
| The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis | Q45869930 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | DNA damage | Q5205747 |
| P304 | page(s) | 98-105 | |
| P577 | publication date | 2001-07-01 | |
| P1433 | published in | Journal of Cellular Physiology | Q1524270 |
| P1476 | title | Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene | |
| P478 | volume | 188 |
| Q32181056 | 3-Hydroxyterphenyllin, a natural fungal metabolite, induces apoptosis and S phase arrest in human ovarian carcinoma cells |
| Q40023794 | A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis |
| Q40641394 | Activation of conventional PKC isoforms increases expression of the pro-apoptotic protein Bad and TRAIL receptors |
| Q60309696 | An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFRα Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma |
| Q38800583 | An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium. |
| Q35092230 | Apoptotic signaling cascades. |
| Q40569371 | Apoptotic signaling in response to a single type of DNA lesion, O(6)-methylguanine. |
| Q39402408 | Camptothecin fails to induce apoptosis in tumor necrosis factor-alpha-treated HaCaT cells |
| Q35221776 | Cleavage of p53-vimentin complex enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of rheumatoid arthritis synovial fibroblasts |
| Q35972500 | Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer |
| Q47291846 | DDIAS suppresses TRAIL-mediated apoptosis by inhibiting DISC formation and destabilizing caspase-8 in cancer cells. |
| Q28217065 | Death and anti-death: tumour resistance to apoptosis |
| Q40486081 | Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. |
| Q35064380 | Death receptors and their role in dermatology, with particular focus on tumor necrosis factor-related apoptosis-inducing ligand receptors |
| Q79602680 | Enhanced T-cell immunity induced by dendritic cells with phagocytosis of heat shock protein 70 gene-transfected tumor cells in early phase of apoptosis |
| Q40563380 | Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. |
| Q44489218 | Etoposide upregulates Bax-enhancing tumour necrosis factor-related apoptosis inducing ligand-mediated apoptosis in the human hepatocellular carcinoma cell line QGY-7703. |
| Q28206926 | Evidence that the human death receptor 4 is regulated by activator protein 1 |
| Q38748966 | Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition |
| Q83241116 | Expression of TRAIL, DR4, and DR5 in bladder cancer: correlation with response to adjuvant therapy and implications of prognosis |
| Q39690748 | GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis |
| Q36875832 | IL-15 signaling promotes adoptive effector T-cell survival and memory formation in irradiation-induced lymphopenia |
| Q24672792 | Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics |
| Q80761758 | Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway |
| Q39365749 | Modulating Both Tumor Cell Death and Innate Immunity Is Essential for Improving Radiation Therapy Effectiveness |
| Q42042886 | Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance. |
| Q36952911 | Nip the HPV encoded evil in the cancer bud: HPV reshapes TRAILs and signaling landscapes |
| Q34708014 | Preferential targeting of apoptosis in tumor versus normal cells |
| Q40125508 | Radioresponsive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy for malignant brain tumors |
| Q37992546 | Resistance to TRAIL and how to surmount it. |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q40442333 | Selection for TRAIL resistance results in melanoma cells with high proliferative potential |
| Q34466979 | Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis |
| Q45316772 | TP53 Regulates Transcription of Cell Death Genes |
| Q45316773 | TP53 Regulates Transcription of Death Receptors and Ligands |
| Q50290181 | TP53 stimulates transcription of TNFRSF10A, TNFRSF10B,TNFRSF10C and TNFRSF10D genes |
| Q35756895 | TRAIL and viral infection |
| Q37719944 | TRAIL combinations: The new 'trail' for cancer therapy (Review). |
| Q35239558 | TRAIL-induced apoptosis is enhanced by heat shock protein 70 expression |
| Q37356520 | Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide |
| Q28071415 | The Double Role of p53 in Cancer and Autoimmunity and Its Potential as Therapeutic Target |
| Q89920520 | The Role of p53-Mediated Signaling in the Therapeutic Response of Colorectal Cancer to 9F, a Spermine-Modified Naphthalene Diimide Derivative |
| Q39673506 | The expression ofp53-regulated genes in human cultured lymphoblastoid TSCE5 and WTK1 cell lines during spaceflight |
| Q37059750 | The role of TRAIL death receptors in the treatment of hematological malignancies |
| Q35756856 | Transcriptional regulation of the TRAIL-R3 gene |
| Q40605290 | Translational control of tumor necrosis factor-related apoptosis-inducing ligand death receptor expression in melanoma cells |
| Q40615752 | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site. |
| Q42428099 | Two overlapping domains of a lyssavirus matrix protein that acts on different cell death pathways |
| Q38967029 | Urokinase-type plasminogen activator receptor regulates apoptotic sensitivity of colon cancer HCT116 cell line to TRAIL via JNK-p53 pathway |
Search more.